Screener
Dianthus Therapeutics DNTH Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001690585-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Loss on investment in former related party | (302) | (5) |
| Loss on currency exchange, net | (15) | (22) |
| Other expense | (249) | (98) |
| Total other income | 5,699 | 3,666 |
| Net loss | $(40,834) | $(29,511) |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.85) | $(0.82) |
| Weighted-average number of shares of common stock outstanding including shares issuable under equity-classified pre-funded warrants, used in computing net loss per share of common stock, basic and diluted | 48,032,742 | 35,790,700 |
| Comprehensive loss: |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dianthus Therapeutics's other income (expense)?
- Dianthus Therapeutics (DNTH) reported other income (expense) of $5.7M in Q1 2026.
- How has Dianthus Therapeutics's other income (expense) changed year-over-year?
- Dianthus Therapeutics's other income (expense) increased by 55.5% year-over-year, from $3.67M to $5.7M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Dianthus Therapeutics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude